Kiora Operating Income from 2010 to 2024
| KPRX Stock | USD 3.32 0.05 1.48% |
Operating Income | First Reported 2013-03-31 | Previous Quarter -2.4 M | Current Value -3.6 M | Quarterly Volatility 2.8 M |
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
Kiora | Operating Income |
Latest Kiora Pharmaceuticals' Operating Income Growth Pattern
Below is the plot of the Operating Income of Kiora Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Kiora Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Kiora Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Kiora Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Kiora Operating Income Regression Statistics
| Arithmetic Mean | (9,252,709) | |
| Coefficient Of Variation | (47.84) | |
| Mean Deviation | 3,871,592 | |
| Median | (8,189,416) | |
| Standard Deviation | 4,426,173 | |
| Sample Variance | 19.6T | |
| Range | 14.5M | |
| R-Value | (0.70) | |
| Mean Square Error | 10.7T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | (696,239) | |
| Total Sum of Squares | 274.3T |
Kiora Operating Income History
About Kiora Pharmaceuticals Financial Statements
Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -12.6 M | -13.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.